MAHON PAUL A sold $4.7M of UTHR
MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $564.95 ($558.30–$573.15, $4.69M total) across 10 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure but modest in size; it may cause slight short‑term pressure but is unlikely to move the stock materially.
Market read
Primary insider filing; modest relevance for short‑term traders monitoring insider activity.
What to watch
The 10b5‑1 plan may have been set up before any material news, reducing the informational value of the transaction.
Background
United Therapeutics (NASDAQ: UTHR) filed a Form 4 reporting an insider sale by its EVP & General Counsel under a pre‑arranged 10b5‑1 plan.
Ticker impact
SEC Form 4 shows EVP & General Counsel Paul Mahon sold 8,300 shares for $4.69M via a 10b5‑1 plan.
likely slight downward pressure as the market prices the insider sell
A C‑suite insider sold shares worth under $5M using a pre‑arranged plan; such sales typically have limited impact but can signal short‑term weakness.
Market effects
Minimal effect on the biotech/therapeutics sector; the sale is company‑specific.
No broader regional impact.
Limited to investors tracking insider activity.
Counterpoint
The sale could be a routine liquidity event and not indicative of any negative fundamentals.
Key entities
- companyUnited Therapeutics Corp
Biopharma company listed on NASDAQ (UTHR).
- insiderPaul Mahon
EVP & General Counsel of United Therapeutics.
